Abbvie Deutschland Gmbh and Co Kg

Abbvie Inc.

Basf Aktiengesellschaft

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Foseco International Limited

Martin Schmidt

Achim Moeller

Reinhold Mueller

Bernhard K Mueller

Eve H Barlow

Chung-Ming Hsieh

Nicole Teusch

Sean Colm Turner

Michael Ochse

Tariq Ghayur

Mario Mezler

Ulrich Ebert

Elizabeth Louise Van Der Kam

Ralf Loebbert

Axel Meyer

Andreas Kling

Helmut Mack

Kevin B Sippy

Heinz Hillen

Frauke Pohlki

Ramin Faghih

Jijie Gu

Mary Leddy

Volker Nimmrich

Philip D Bardwell

John E Harlan

Enrico L Digiammarino

Gerard B Fox

Feng Luo

Zhen Wu

Wilfried Hornberger

Andreas Haupt

Gerd Steiner

Udo Lange

Burkhard Kröger

Anil Vasudevan

Karsten M Wicke

Thomas Subkowski

Werner Seitz

Michael Schulz

Thomas Friedrich

Claus Bollschweiler

Hans Wolfgang Höffken

Jürgen Dinges

Helmut Jaunich

David L Jones

Axel Leimer

Kassim Juma

Harald Seulberger

Achim Möller

Jurgen Schweden

Rainer Otter

Thomas Meyer

Alfred Hahn

Margaretha Bakker

Johann-Christian Zechel

David A Bell

Kurt Schellhaas

Martin Raditsch

Elard Jacob

Klaus Rübsamen

Andreas Ansorge

Mary R Leddy

Phillip D Bardwell

Lin Roemer

Bernhard K MÜLLER

David Llewellyn Jones

David Alan Bell

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, Rand Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the &#x3b3;-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Land Gare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the &#x3b3;-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Substituted pyrazolopyrimidines and method of use

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Antibodies against the RGM a protein and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.

AGER-peptides and use thereof

Antibodies against the RGM A protein and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

A process for making a filter suitable for filtering molten metal comprising (i) forming a slurry comprising (a) particles of a refractory material, (b) a binder and (c) a liquid carrier, (ii) coating a disposable former with a slurry, (iii) drying the coated former, (iv) optionally applying one or more additional coats of a refractory material and/or a binder, optionally with liquid carrier, and drying the one or more additional coats, and (v) firing the coated former to produce the filter, wherein the binder is a carbon rich source selected from one or more of the following classes of materials: pitches, tars and organic polymers that degrade to form carbon on pyrolysis.

Refractory articles

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)

3-Substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof. The invention relates to 3,4-dihydrothieno[2,3-d]pyrimidin-4-one derivatives which are substituted in position 3 by 5-membered heteroaryl which may be fused to an aryl or heteroaryl radical, where the heteroaryl and, if appropriate, the fused aryl or heteroaryl radical may have 1, 2 or 3 substituents selected independently of one another from C-alkyl, C-alkoxy, C-alkylthio, halogen, CN, halo-C-alkyl, halo-C-alkoxy, hydroxy, &#x2014;NH, &#x2014;N(R6), &#x2014;NH(R6), aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl, where the substituents aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl may have 1, 2 or 3 substituents selected independently of one another from C-alkyl, C-alkoxy, C-alkylthio, halogen, CN, halo-C-alkyl, halo-C-alkoxy, hydroxy, &#x2014;NH, &#x2014;N(R6)and &#x2014;NH(R6). The preparation and use of these derivatives, especially for therapeutic purposes, e.g. for the treatment of depressions, are likewise described.

3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof

Peptide substances, their preparation and their use as complement inhibitors are described. These are in particular substances having a guanidine or amidine radical as a terminal group. In particular, inhibitors of the complement proteases C1s and C1r are described.

Low molecular weight inhibitors of complement proteases

Endothelin converting enzyme (ECE)

Growing community of inventors

Bensheim, Germany

Martin Schmidt